Christian B Gocke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1443738/publications.pdf

Version: 2024-02-01

		1163117	1199594	
13	282	8	12	
papers	citations	h-index	g-index	
13	13	13	558	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematology,the, 2019, 6, e183-e193.	4.6	111
2	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non–First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102.	2.0	61
3	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Advances, 2020, 4, 5078-5088.	5.2	23
4	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Advances, 2019, 3, 2608-2616.	5.2	20
5	Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. Npj Precision Oncology, 2021, 5, 38.	5.4	18
6	Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Research, 2019, 17, 929-936.	3.4	11
7	Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplantation and Cellular Therapy, 2022, 28, 259.e1-259.e11.	1.2	11
8	IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal. Molecular Cancer Therapeutics, 2016, 15, 2733-2739.	4.1	10
9	An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. Clinical Cancer Research, 2021, 27, 6696-6708.	7.0	8
10	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 863.e1-863.e5.	1,2	4
11	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 260-269.	0.4	4
12	The Drowning Heart: An Ambiguous Lymphoma. American Journal of Medicine, 2014, 127, 817-819.	1.5	1
13	Inhibiting Oncogenic RAS in Multiple Myeloma By Targeting Scaffold-ERK Interactions. Blood, 2014, 124, 2089-2089.	1.4	0